There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vanda (VNDA – Research Report) and Vigil Neuroscience Inc (VIGL – Research Report) with bullish sentiments.
Vanda (VNDA)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Vanda today and set a price target of $18.00. The company’s shares closed last Thursday at $5.02.
According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 9.7% and a 46.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, MoonLake Immunotherapeutics, and Entrada Therapeutics Inc.
Vanda has an analyst consensus of Moderate Buy, with a price target consensus of $15.50, implying a 222.9% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $13.00 price target.
See the top stocks recommended by analysts >>
Vigil Neuroscience Inc (VIGL)
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Vigil Neuroscience Inc today and set a price target of $17.00. The company’s shares closed last Thursday at $3.57.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 15.9% and a 52.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Zentalis Pharmaceuticals, and KalVista Pharmaceuticals.
Currently, the analyst consensus on Vigil Neuroscience Inc is a Moderate Buy with an average price target of $14.67.
Read More on VNDA: